Systemic therapy of hepatocellular carcinoma: Current status and future perspectives

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3087-3099

  Germano, Domenico ^a   Daniele, Bruno ^a  

^a G RUMMO HOSPITAL   (Italy)

Author keywords

Hepatocellular carcinoma; Molecular agents; Sorafenib; Targheted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NOLATREXED; OCTREOTIDE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAF PROTEIN; RAMUCIRUMAB; SOMATOMEDIN B; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TIVANTINIB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; GLYPICAN; GPC3 PROTEIN, HUMAN; HORMONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOEMBOLIZATION; CLINICAL PRACTICE; HEPATOCYTE TRANSPLANTATION; HORMONAL THERAPY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FUNCTION; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TUMOR NECROSIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; LIVER NEOPLASMS; METABOLISM; ONCOLOGY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; GLYPICANS; HORMONES; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE KINASES; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84896957174     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3087     Document Type: Article

References (82)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
2. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-432 [PMID: 17597707 DOI: 10.1038/ ncponc0844]
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterol-ogy 2008; 134: 1752-1763 [PMID: 18471552 DOI: 10.1053/ j.gastro.2008.02.090]
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 Suppl 1: S20-S37 [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022]
5. Clavien PA. Interferon: the magic bullet to prevent he-patocellular carcinoma recurrence after resection? Ann Surg 2007; 245: 843-845 [PMID: 17522507 DOI: 10.1097/ SLA.0b013e31805d0788]
6. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. He-patocellular carcinoma: systemic treatments. J Clin Gastroen-terol 2002; 35: S109-S114 [PMID: 12394214 DOI: 10.1097/0000 4836-200211002-00007]
7. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 1999; 135: 97-105 [PMID: 10077227 DOI: 10.1016/ S0304-3835(98)00280-8]
8. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nak-agawa K, Shimizu H, Yokosuka O, Nakajima N. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001; 78: 110-115 [PMID: 11579388 DOI: 10.1002/jso.1129]
9. Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Mo-rabito A, Piccirillo MC, Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroen-terol 2008; 14: 1682-1689 [PMID: 18350599 DOI: 10.3748/ wjg.14.1682]
10. Francavilla A, Polimeno L, DiLeo A, Barone M, Ove P, Coe-tzee M, Eagon P, Makowka L, Ambrosino G, Mazzaferro V. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989; 9: 614-620 [PMID: 2784403 DOI: 10.1002/hep.1840090417]
11. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995; 21: 1535-1542 [PMID: 7768497]
12. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils J. Evaluation of antian-drogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998; 16: 411-417 [PMID: 9469323]
13. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Mos-chandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442-447 [PMID: 9577356 DOI: 10.1136/gut.42.3.442]
14. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36: 687-691 [PMID: 12198662 DOI: 10.1053/jhep.2002.35071]
15. Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9-15 [PMID: 17187405 DOI: 10.1002/hep.21468]
16. Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23: 4338-4346 [PMID: 15994145 DOI: 10.1200/JCO.2005.05.470]
17. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvani-takis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multi-centre phase III study. Br J Cancer 2007; 97: 582-588 [PMID: 17687341 DOI: 10.1038/sj.bjc.6603901]
18. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisi-mopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepato-cellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007; 13: 3164-3170 [PMID: 17589893]
19. Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhil-lon H, Gebski V. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced he-patocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006; 95: 853-861 [PMID: 16953241 DOI: 10.1038/ sj.bjc.6603325]
20. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985; 56: 2751-2755 [PMID: 2413981]
21. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15: 1-31 [PMID: 2834053 DOI: 10.1016/0305-7372(88)90007-2]
22. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocel-lular carcinoma. Clin Cancer Res 1999; 5: 1676-1681 [PMID: 10430068]
23. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fuorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538 [PMID: 16234567 DOI: 10.1093/jnci/ dji315]
24. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25: 3069-3075 [PMID: 17634485 DOI: 10.1200/JCO.2006.08.4046]
25. Posey J, Johnson P, Mok T. Results of a phase 2/3 open-label, randomized trial of T138067 vs doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2005; 23: 4035a
26. Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastro-enterol 2008; 14: 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1]
27. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346 [PMID: 12149612 DOI: 10.1038/ng0802-339]
28. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300 [PMID: 16908937 DOI: 10.1200/ JCO.2005.01.3441]
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
30. Cheng A, Kang Y, Chen Z. Randomized phase III trial of sorafenib vs placebo in Asian patients with advanced hepa-tocellular carcinoma. J Clin Oncol 2008; 26: abstr4509
31. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced he-patocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160 [PMID: 21081728 DOI: 10.1001/jama.2010.1672]
32. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004; 57: 867-871 [PMID: 15280410 DOI: 10.1136/ jcp.2003.015784]
33. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997; 27: 854-861 [PMID: 9382973 DOI: 10.1016/S0168-8278(97)80323-6]
34. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77 [PMID: 9657098 DOI: 10.1002/hep.510280111]
35. Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ, Kojiro M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000; 7: 725-729 [PMID: 10854533]
36. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepato-cellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355-362 [PMID: 12734082 DOI: 10.1245/ASO.2003.10.002]
37. Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH, Wang HY. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in respectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 2004; 10: 643-648 [PMID: 14991930]
38. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-1360 [PMID: 15376182 DOI: 10.1002/ bjs.4594]
39. Jain RK. Normalizing tumor vasculature with anti-angio-genic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989 [PMID: 11533692 DOI: 10.1038/ nm0901-987]
40. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147 [PMID: 14745444 DOI: 10.1038/nm988]
41. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998 [PMID: 18565886 DOI: 10.1200/JCO.2007.15.9947.]
42. Malka D, Dromain C, Farace F. Bevacizumab in patients with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007; 25 (Suppl): 4570
43. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903 [PMID: 16622265 DOI: 10.1200/JCO.2005.04.9130]
44. Sun W, Haller DG, Mykulowycz K Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol 2007; 25 (Suppl): 457
45. Hsu C, Yang T, Hsu C. Modifed-dose capecitabine bevaci-zumab for the treatment of advanced/metastatic hepatocel-lular carcinoma (HCC): a phase II, single-arm study. J Clin Oncol 2007; 25 (Suppl): 15190
46. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850 [PMID: 19139433 DOI: 10.1200/ JCO.2008.18.3301]
47. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lah-denranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomark-ers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035 [PMID: 19470923 DOI: 10.1200/JCO.2008.20.9908]
48. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL. Safety and effcacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10: 794-800 [PMID: 19586800 DOI: 10.1016/ S1470-2045(09)70171-8]
49. Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S. Phase III trial of sunitinib (Su) vs sorafenib (So) in advanced hepato-cellular carcinoma (HCC). J Clin Oncol 2011; 29 (Suppl): abstr 4000
50. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-2098 [PMID: 22238246 DOI: 10.1158/1078-0432.CCR-11-1991]
51. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Far-toux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31: 3509-3516 [PMID: 23980090 DOI: 10.1200/JCO.2012.47.3009]
52. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslid-suk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ez-zeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as frst-line therapy in patients with unresectable, advanced he-patocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524 [PMID: 23980084]
53. Toh H, Chen P, Carr BI. A phase II study of ABT-869 in he-patocellular carcinoma (HCC): interim analysis. J Clin Oncol 2009; 27 (Suppl): 4581
54. Yau CC, Chen PJ, Curtis CM. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009; 27 (Suppl): 3561
55. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2012; 35: 329-333 [PMID: 21422991 DOI: 10.1097/ COC.0b013e3182118cdf]
56. Koch I, Baron A, Roberts S. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (pts) with unresectable he-patocellular carcinoma (HCC). J Clin Oncol 2007; 23 (Suppl): 4134
57. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI: 10.1016/ S1470-2045(12)70490-4]
58. Zhu AX, Finn RS, Mulcahy MF, Gurtler JS, Sun W, Schwartz, P. Rojas, A. Dontabhaktuni, H. Youssoufan and K. E. Stuart. A phase II study of ramucirumab as frst-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2010; 28 (15s): 4083
59. Carlin CR, Simon D, Mattison J, Knowles BB. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol Cell Biol 1988; 8: 25-34 [PMID: 2827003]
60. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999; 19: 318-325 [PMID: 10459631 DOI: 10.1111/j.1478-3231.1999. tb00056.x]
61. Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsu-jimoto M, Monden M, Matsuura N. Expression of heparin binding epidermal growth factor-like growth factor in hepa-tocellular carcinoma: an immunohistochemical study. Oncol Rep 2001; 8: 903-907 [PMID: 11410807]
62. Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocel-lular carcinoma. Liver 1997; 17: 177-182 [PMID: 9298487 DOI: 10.1111/j.1600-0676.1997.tb00803.x]
63. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997; 3: 1059-1066 [PMID: 9815784]
64. Yeh YC, Tsai JF, Chuang LY, Yeh HW, Tsai JH, Florine DL, Tam JP. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987; 47: 896-901 [PMID: 2433030]
65. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced he-patocellular cancer. J Clin Oncol 2005; 23: 6657-6663 [PMID: 16170173 DOI: 10.1200/JCO.2005.14.696]
66. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlo-tinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-1067 [PMID: 17623837 DOI: 10.1002/ cncr.22886]
67. O'Dwyer PJ, Giantonio BJ, Levy DE. Geftinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006; 24 (Suppl): 4143
68. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783 [PMID: 19169683 DOI: 10.1007/s00280-009-0927-7]
69. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-589 [PMID: 17583545 DOI: 10.1002/cncr.22829]
70. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louaf S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008; 112: 2733-2739 [PMID: 18412149 DOI: 10.1002/cncr.23489]
71. O'Neil BH, Bernard SA, Goldberg RM. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepa-tocellular carcinoma. J Clin Oncol 2008; 26 (Suppl): 4604
72. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Wax-man S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983 [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008]
73. Chen L, Shiah HS, Chen CY. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009; 27 (Suppl): 4587
74. US National Institutes of Health. Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma (EVOLVE-1).Avail-able from: URL: http://clinicaltrials.gov/ct2/show/ NCT01035229?term=EVOLVE-1&rank=1
75. O'Neil BH, Williams-Goff LW, Kauh J. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2009; 27 (Suppl): e15574
76. Li M, Choo B, Wong ZM, Filmus J, Buick RN. Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res 1997; 235: 3-12 [PMID: 9281346 DOI: 10.1006/excr.1997.3629]
77. Farooq M, Hwang SY, Park MK, Kim JC, Kim MK, Sung YK. Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. Mol Cells 2003; 15: 356-360 [PMID: 12872992]
78. Huber R, Hansen RS, Strazzullo M, Pengue G, Mazzarella R, D'Urso M, Schlessinger D, Pilia G, Gartler SM, D'Esposito M. DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1. Proc Natl Acad Sci USA 1999; 96: 616-621 [PMID: 9892682 DOI: 10.1073/pnas.96.2.616]
79. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midori-kawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005; 18: 1591-1598 [PMID: 15920546]
80. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gas-troenterology 2006; 131: 1758-1767 [PMID: 17087938]
81. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 2005; 19: 71-77 [PMID: 15807627 DOI: 10.2165/00063030-200519020-00001]
82. Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH, Cheng AL. Prognosis of patients with advanced hepa-tocellular carcinoma who failed frst-line systemic therapy. J Hepatol 2014; 60: 313-318 [PMID: 24036008 DOI: 10.1016/ j.jhep.2013.08.027]